XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more
XSpray Pharma AB (XSPRAY) - Net Assets
Latest net assets as of September 2025: Skr641.73 Million SEK
Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has net assets worth Skr641.73 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr820.20 Million) and total liabilities (Skr178.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr641.73 Million |
| % of Total Assets | 78.24% |
| Annual Growth Rate | 54.71% |
| 5-Year Change | 6.95% |
| 10-Year Change | N/A |
| Growth Volatility | 101.22 |
XSpray Pharma AB - Net Assets Trend (2015–2024)
This chart illustrates how XSpray Pharma AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for XSpray Pharma AB (2015–2024)
The table below shows the annual net assets of XSpray Pharma AB from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr623.10 Million | -10.14% |
| 2023-12-31 | Skr693.41 Million | +24.71% |
| 2022-12-31 | Skr556.02 Million | -6.04% |
| 2021-12-31 | Skr591.75 Million | +1.57% |
| 2020-12-31 | Skr582.59 Million | +55.89% |
| 2019-12-31 | Skr373.71 Million | +23.86% |
| 2018-12-31 | Skr301.72 Million | +93.83% |
| 2017-12-31 | Skr155.66 Million | +234.94% |
| 2016-12-31 | Skr46.47 Million | +278.98% |
| 2015-12-31 | Skr12.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to XSpray Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10641.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr37.14 Million | 5.96% |
| Other Comprehensive Income | Skr998.00K | 0.16% |
| Other Components | Skr1.43 Billion | 228.73% |
| Total Equity | Skr623.10 Million | 100.00% |
XSpray Pharma AB Competitors by Market Cap
The table below lists competitors of XSpray Pharma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Himatsingka Seide Limited
NSE:HIMATSEIDE
|
$67.54 Million |
|
Lassila &Tikanoja Oyj
HE:LAT1V
|
$67.58 Million |
|
CI Games SA
WAR:CIG
|
$67.58 Million |
|
INTRON TECH.HLDGS HD -01
F:B46
|
$67.59 Million |
|
Alterity Therapeutics Ltd
NASDAQ:ATHE
|
$67.51 Million |
|
Harrisons Holdings (Malaysia)
KLSE:5008
|
$67.50 Million |
|
Carlo Gavazzi Holding AG
SW:GAV
|
$67.49 Million |
|
Cupid Limited
NSE:CUPID
|
$67.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XSpray Pharma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 693,413,000 to 623,097,000, a change of -70,316,000 (-10.1%).
- Net loss of 285,523,000 reduced equity.
- Share repurchases of 236,520,000 reduced equity.
- New share issuances of 236,520,000 increased equity.
- Other comprehensive income increased equity by 999,000.
- Other factors increased equity by 214,208,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-285.52 Million | -45.82% |
| Share Repurchases | Skr236.52 Million | -37.96% |
| Share Issuances | Skr236.52 Million | +37.96% |
| Other Comprehensive Income | Skr999.00K | +0.16% |
| Other Changes | Skr214.21 Million | +34.38% |
| Total Change | Skr- | -10.14% |
Book Value vs Market Value Analysis
This analysis compares XSpray Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.31x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 25.12x to 1.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr0.98 | Skr24.70 | x |
| 2016-12-31 | Skr7.25 | Skr24.70 | x |
| 2017-12-31 | Skr18.36 | Skr24.70 | x |
| 2018-12-31 | Skr21.27 | Skr24.70 | x |
| 2019-12-31 | Skr24.34 | Skr24.70 | x |
| 2020-12-31 | Skr33.54 | Skr24.70 | x |
| 2021-12-31 | Skr30.48 | Skr24.70 | x |
| 2022-12-31 | Skr26.15 | Skr24.70 | x |
| 2023-12-31 | Skr26.07 | Skr24.70 | x |
| 2024-12-31 | Skr18.80 | Skr24.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently XSpray Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.28x
- Recent ROE (-45.82%) is below the historical average (-25.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -98.60% | -332.17% | 0.24x | 1.22x | Skr-13.32 Million |
| 2016 | -8.82% | -517.30% | 0.02x | 1.12x | Skr-8.74 Million |
| 2017 | -8.48% | -3980.86% | 0.00x | 1.04x | Skr-28.76 Million |
| 2018 | -7.66% | -8338.63% | 0.00x | 1.04x | Skr-53.27 Million |
| 2019 | -12.27% | 0.00% | 0.00x | 1.07x | Skr-83.21 Million |
| 2020 | -8.98% | 0.00% | 0.00x | 1.04x | Skr-110.56 Million |
| 2021 | -16.34% | 0.00% | 0.00x | 1.05x | Skr-155.88 Million |
| 2022 | -23.43% | 0.00% | 0.00x | 1.05x | Skr-185.87 Million |
| 2023 | -25.91% | 0.00% | 0.00x | 1.10x | Skr-249.01 Million |
| 2024 | -45.82% | 0.00% | 0.00x | 1.28x | Skr-347.83 Million |
Industry Comparison
This section compares XSpray Pharma AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $67,040,682
- Average return on equity (ROE) among peers: -54.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XSpray Pharma AB (XSPRAY) | Skr641.73 Million | -98.60% | 0.28x | $67.54 Million |
| 2cureX AB (2CUREX) | $5.10 Million | -80.96% | 0.52x | $1.36 Million |
| Abliva AB (ABLI) | $11.70 Million | -13.32% | 0.05x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $25.35 Million |
| AcouSort AB (ACOU) | $33.02 Million | -37.49% | 0.11x | $4.42 Million |
| Active Biotech AB (ACTI) | $22.11 Million | -145.24% | 0.45x | $3.51 Million |
| Alzinova AB (ALZ) | $88.47 Million | -8.57% | 0.04x | $4.41 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $12.95 Million |
| Annexin Pharmaceuticals AB (ANNX) | $-137.00K | 0.00% | 0.00x | $4.76 Million |
| Alligator Bioscience AB (ATORX) | $258.50 Million | -81.44% | 0.20x | $727.42K |
| Biosergen AS (BIOSGN) | $-4.69 Million | 0.00% | 0.00x | $2.84 Million |